News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim Corporation Release: Cost Effectiveness and Clinical Efficacy of Pradaxa® (Dabigatran Etexilate) Versus Rivaroxaban Analysed


8/24/2012 10:01:38 AM

INGELHEIM, Germany--(BUSINESS WIRE)-- In the absence of a head-to-head study, a comprehensive analysis published in Thrombosis and Hemostasis,1 looks into the efficacy and cost-effectiveness of Pradaxa® for stroke prevention in patients with non-valvular atrial fibrillation in an indirect comparison to rivaroxaban. The analysis, based on two large scale trials including more than 32.000 patients combined, suggests that patients treated with Pradaxa® may have lower rates of ischaemic stroke and intracranial haemorrhage (ICH), and also accumulate lower costs from acute care and long-term follow-up over their lifetime than patients treated with rivaroxaban.1

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES